In the present study, we aimed to evaluate the kinetics of BCR::ABL1 transcripts during the de-escalation and discontinuation phases of the DES-CML TKI discontinuation trial and the impact on treatment-free survival (TFS). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.